Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China 
South Korea Factory Activity Hits 18-Month High as Export Demand Surges 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
EU Recovery Fund Faces Bottlenecks Despite Driving Digital and Green Projects 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Disaster or digital spectacle? The dangers of using floods to create social media content 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
